Vanguard Group Inc. Lowers Stake in TG Therapeutics, Inc. $TGTX

Vanguard Group Inc. lowered its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 1.8% in the third quarter, Holdings Channel reports. The firm owned 15,521,299 shares of the biopharmaceutical company’s stock after selling 288,018 shares during the period. Vanguard Group Inc. owned approximately 0.10% of TG Therapeutics worth $560,707,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of TGTX. Johnson Financial Group Inc. purchased a new stake in TG Therapeutics during the second quarter worth approximately $25,000. Bessemer Group Inc. lifted its holdings in shares of TG Therapeutics by 117.1% during the 3rd quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 486 shares in the last quarter. Salomon & Ludwin LLC purchased a new stake in TG Therapeutics during the 3rd quarter worth $34,000. Stone House Investment Management LLC acquired a new stake in TG Therapeutics in the 3rd quarter valued at $36,000. Finally, EverSource Wealth Advisors LLC raised its position in TG Therapeutics by 86.3% in the second quarter. EverSource Wealth Advisors LLC now owns 1,237 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 573 shares during the period. 58.58% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Weiss Ratings reiterated a “hold (c+)” rating on shares of TG Therapeutics in a research note on Monday, December 29th. Cantor Fitzgerald reiterated an “overweight” rating on shares of TG Therapeutics in a research report on Wednesday, January 14th. Wall Street Zen lowered TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. B. Riley Financial upgraded TG Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 4th. Finally, The Goldman Sachs Group boosted their target price on shares of TG Therapeutics from $37.00 to $39.00 and gave the company a “neutral” rating in a research note on Thursday, January 15th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $50.00.

TG Therapeutics Stock Performance

TGTX stock opened at $30.51 on Wednesday. The company has a 50-day simple moving average of $29.88 and a 200 day simple moving average of $31.41. The company has a market capitalization of $4.84 billion, a P/E ratio of 10.97 and a beta of 1.85. The company has a quick ratio of 2.89, a current ratio of 3.82 and a debt-to-equity ratio of 0.40. TG Therapeutics, Inc. has a fifty-two week low of $25.28 and a fifty-two week high of $46.48.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.